Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Status Terminated

Clinical Trial Summary

Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.

Clinical Trial Description

Anti-depressants have been shown to be beneficial in cancer participants. They reduce depressive symptoms and improve quality of life. Randomized trials have shown that antidepressants can reduce the development of depression in non-depressed participants with breast, melanoma, and head and neck cancers. It has been shown that treating depression can impact survival in cancer participants. Additionally, depressed pancreatic cancer participants have worse survival. Therefore, anti-depressants may also have implications for cancer treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05289830
Study type	Interventional
Source	Case Comprehensive Cancer Center
Contact
Status	Terminated
Phase	Phase 2
Start date	August 5, 2022
Completion date	August 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05209074` - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma	Phase 1
Recruiting	`NCT04969731` - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer	Phase 3
Recruiting	`NCT04927780` - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer	Phase 3
Recruiting	`NCT05048524` - Peri-operative SLOG for Localized Pancreatic Cancer	Phase 2
Terminated	`NCT04042480` - A Study of SGN-CD228A in Advanced Solid Tumors	Phase 1
Completed	`NCT03257150` - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer	N/A
Terminated	`NCT04400903` - Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Active, not recruiting	`NCT05462717` - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Phase 1
Active, not recruiting	`NCT03267316` - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	Phase 1/Phase 2
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Terminated	`NCT04046887` - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)	Phase 1
Recruiting	`NCT05964621` - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Active, not recruiting	`NCT04827953` - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer	Phase 1/Phase 2
Recruiting	`NCT04291651` - UCSF PANC Cyst Registry
Recruiting	`NCT05977322` - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.	Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting	`NCT04853017` - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors	Phase 1
Active, not recruiting	`NCT04862260` - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma	Early Phase 1
Completed	`NCT03770117` - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed	`NCT02259114` - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	Phase 1